Press Releases Year None20262025202420232022202120202019201820172015 June 5, 2026 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) May 27, 2026 ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences May 4, 2026 ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates May 1, 2026 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) April 17, 2026 ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual Meeting April 3, 2026 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) March 31, 2026 ORIC® Pharmaceuticals Reports Selection of Rinzimetostat RP3D in Combination with Darolutamide for Himalayas-1 Phase 3 Global Study with Dose Optimization Data Supporting Its Potential Best-in-Disease Profile March 27, 2026 ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC March 17, 2026 ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat (ORIC-944) Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting March 6, 2026 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 15
OricPharma logo
